‘We’ll Be First With Off-The-Shelf CAR-T,’ Vows Precision Biosciences – And Hopes To Win Over Gene-Editing Skeptics
Aiming To Help Patients Who Fail Auto CAR-Ts
As it and its competitors have failed on the first test of durability with their allogeneic CAR-T candidates, Precision Biosciences is looking to cross the line in a sub-group of responders – as well as prove the value of its gene-editing platform.
You may also be interested in...
Precision is looking ahead to market access challenges for its off-the-shelf CAR-T and in vivo gene-editing therapies.
Roche will suffer a hangover from its COVID-19 successes this year as revenues stagnate and its future strategy is yet to be laid out by incoming CEO Thomas Schinecker.
Having outperformed in 2022, GSK is gearing up for key regulatory and market access decisions on its RSV vaccine, but is confident it holds superior data compared with rival Pfizer.